Table S4 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy

Synergy scores obtained from LSCC cell lines treated with NCB-0846 in combination with cisplatin/etoposide with NCB-0846 as the pretreatment. Cell viability was evaluated 48h after the addition of cisplatin/etoposide.